Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.31
-0.19 (-2.00%)
At close: Apr 13, 2026, 4:00 PM EDT
9.35
+0.04 (0.43%)
After-hours: Apr 13, 2026, 7:18 PM EDT
Vir Biotechnology Employees
Vir Biotechnology had 367 employees as of December 31, 2025. The number of employees decreased by 41 or -10.05% compared to the previous year.
Employees
367
Change (1Y)
-41
Growth (1Y)
-10.05%
Revenue / Employee
$186,801
Profits / Employee
-$1,193,425
Market Cap
1.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 367 | -41 | -10.05% |
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Sep 30, 2021 | 395 | 98 | 33.00% |
| Jun 30, 2021 | 367 | 114 | 45.06% |
| Mar 31, 2021 | 340 | 103 | 43.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 298 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Nanobiotix | 103 |
VIR News
- 17 hours ago - Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer - Business Wire
- 6 weeks ago - Vir Biotechnology to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Vir Biotechnology Announces Pricing of Public Offering of Common Stock - Business Wire
- 6 weeks ago - Vir Biotechnology Announces Proposed Public Offering of Common Stock - Business Wire
- 6 weeks ago - These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga
- 6 weeks ago - What's Happening With VIR Stock? - Forbes
- 7 weeks ago - Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 7 weeks ago - Astellas collaborates with Vir to develop its experimental prostate cancer drug - Reuters